尔康制药 reported revenue of ¥0.57B for the period ended 2026-06-30, -16.8% year on year. Net income was ¥0.03B, a 6.0% net margin on a 31.4% gross margin. The largest revenue line is 辅料 at 65% of the total. Free cash flow for the period was ¥-0.19B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.57B | -16.8% |
| Gross profit | ¥0.18B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.03B | +17.6% |
| Gross margin | 31.4% | Net margin 6.0% |
| Revenue Q/Q | +29.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 辅料 | ¥0.37B | 64.7% |
| 新能源材料 | ¥0.10B | 16.9% |
| 原料药 | ¥0.06B | 9.9% |
| 成品药 | ¥0.04B | 6.3% |
| 其他 | ¥0.01B | 1.8% |
| 其他主营业务 | ¥0.00B | 0.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.39B | 68.6% |
| R&D | ¥0.02B | 4.0% |
| SG&A | ¥0.11B | 19.9% |
| Tax & other | ¥0.01B | 1.1% |
| Item | Amount |
|---|---|
| Total assets | ¥4.98B |
| Total liabilities | ¥1.03B |
| Shareholders' equity | ¥3.95B |
| Equity / assets | 79.4% |
| Operating cash flow | ¥-0.14B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥-0.19B |
| Cash conversion (OCF / net income) | -455% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
佳沃食品 ・ 联建光电 ・ 中威电子 ・ 华宇软件 ・ 开能健康 ・ 梅安森 ・ 三丰智能 ・ 汽轮科技 ・ 华昌达 ・ 和晶科技 ・ 金明精机 ・ 温州宏丰
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies